Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 197Bevacizumab 162Fluorouracil 155Capecitabine 137Gemcitabine 133Leucovorin 112pembrolizumab 99Cisplatin 93Drug Therapy 89Irinotecan 81Radiotherapy 73sintilimab 70durvalumab 65130-nm albumin-bound paclitaxel 65Paclitaxel 64Specimen Handling 62Cetuximab 61lenvatinib 59tislelizumab 58Nivolumab 55Magnetic Resonance Spectroscopy 55Folfox protocol 55Blood Specimen Collection 52atezolizumab 48Biopsy 46Surgical Procedures, Operative 40Taxes 38Albumin-Bound Paclitaxel 38Immune Checkpoint Inhibitors 37HMPL-013 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × recombinant interferon alpha 2b-like protein × Gastrointestinal × Clear all
NCT04380545 2026-03-06

Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
15 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡